Jennifer M. Rolland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jennifer M. Rolland has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Creina S. Stockley
Department of Immunology, Monash University, and Department of Allergy, Immunology and Respiratory Medicine, The Alfred, Commercial Road, Melbourne, Victoria, Australia 3004, and The Australian Wine Research Institute, Adelaide, Australia
1 shared publicationEffie Apostolou
Department of Immunology, Monash University, and Department of Allergy, Immunology and Respiratory Medicine, The Alfred, Commercial Road, Melbourne, Victoria, Australia 3004, and The Australian Wine Research Institute, Adelaide, Australia
1 shared publicationJo Douglass
Department of Pathology and Immunology, Monash University Medical School, Commercial Road, Prahran, Victoria 3181, Australia
1 shared publication- Leanne M. Gardner
Research Department of Primary Care and Population Health, University College London, London, UK
1 shared publication Maria P. de Leon
Department of Immunology, Monash University, and Department of Allergy, Immunology and Respiratory Medicine, The Alfred, Commercial Road, Melbourne, Victoria, Australia 3004, and The Australian Wine Research Institute, Adelaide, Australia
1 shared publicationRobyn E O’hEhir
Department of Pathology and Immunology, Monash University Medical School, Commercial Road, Prahran, Victoria 3181, Australia
1 shared publication
Latest Publications
- 1 March 2009
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 121 (3) , 273-284
Allergen-related approaches to immunotherapy
- 1 March 2009
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 121 (3) , 273-284
Allergen-related approaches to immunotherapy
- 29 December 2007
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 56 (2) , 349-354
Specific and Sensitive Enzyme-Linked Immunosorbent Assays for Analysis of Residual Allergenic Food Proteins in Commercial Bottled Wine Fined with Egg White, Milk, and Nongrape-Derived Tannins
Regulations introduced by the Food Standards Australia New Zealand in December 2002 require all wine and wine product labels in Australia to identify the presence of a processing aid, additive or other ingredient, which is known to be a potential allergen. The objective of this study was to establish sensitive assays to detect and measure allergenic proteins from commonly used processing aids in final bottled wine. Sensitive and specific enzyme-linked immunosorbent assays (ELISA) were developed and established for the proteins casein, ovalbumin, and peanut. Lower limits of detection of these proteins were 8, 1, and 8 ng/mL, respectively. A panel of 153 commercially available bottled Australian wines were tested by these ELISA, and except for two red wines known to contain added whole eggs, residuals of these food allergens were not detected in any wine. These findings are consistent with a lack of residual potentially allergenic egg-, milk-, or nut-derived processing aids in final bottled wine produced in Australia according to good manufacturing practice at a concentration that could cause an adverse reaction in egg, milk, or peanut/tree-nut allergic adult consumers.
- 29 December 2007
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 56 (2) , 349-354
Specific and Sensitive Enzyme-Linked Immunosorbent Assays for Analysis of Residual Allergenic Food Proteins in Commercial Bottled Wine Fined with Egg White, Milk, and Nongrape-Derived Tannins
Regulations introduced by the Food Standards Australia New Zealand in December 2002 require all wine and wine product labels in Australia to identify the presence of a processing aid, additive or other ingredient, which is known to be a potential allergen. The objective of this study was to establish sensitive assays to detect and measure allergenic proteins from commonly used processing aids in final bottled wine. Sensitive and specific enzyme-linked immunosorbent assays (ELISA) were developed and established for the proteins casein, ovalbumin, and peanut. Lower limits of detection of these proteins were 8, 1, and 8 ng/mL, respectively. A panel of 153 commercially available bottled Australian wines were tested by these ELISA, and except for two red wines known to contain added whole eggs, residuals of these food allergens were not detected in any wine. These findings are consistent with a lack of residual potentially allergenic egg-, milk-, or nut-derived processing aids in final bottled wine produced in Australia according to good manufacturing practice at a concentration that could cause an adverse reaction in egg, milk, or peanut/tree-nut allergic adult consumers.
- 1 March 2000
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 9 (3) , 515-527
Allergen immunotherapy: current and new therapeutic strategies
Allergic individuals respond to an environmental allergen encounter by producing T-cell cytokines, predominantly IL-4 and IL-5, which in turn drive the production of allergen-specific IgE antibodies and recruitment of an eosinophil-rich inflammatory infiltrate. Allergen-specific immunotherapy (SIT) involves the repeated injection of the allergen to specifically downregulate this predominantly Th2-type immune response. SIT is a clinically proven effective treatment for allergic diseases, including rhinoconjunctivitis and asthma. However, despite having been in clinical practice since early this century, its use remains empirical. Best practice protocols are based on clinical experience and include recommendations for selecting patients for treatment, SIT regimes and avoidance of adverse events. More rational and safer SIT regimes will result from new insights into the underlying immune mechanisms for allergic disease, in particular the critical role of helper T-cells in orchestrating this response. The dev...
- 1 March 2000
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 9 (3) , 515-527
Allergen immunotherapy: current and new therapeutic strategies
Allergic individuals respond to an environmental allergen encounter by producing T-cell cytokines, predominantly IL-4 and IL-5, which in turn drive the production of allergen-specific IgE antibodies and recruitment of an eosinophil-rich inflammatory infiltrate. Allergen-specific immunotherapy (SIT) involves the repeated injection of the allergen to specifically downregulate this predominantly Th2-type immune response. SIT is a clinically proven effective treatment for allergic diseases, including rhinoconjunctivitis and asthma. However, despite having been in clinical practice since early this century, its use remains empirical. Best practice protocols are based on clinical experience and include recommendations for selecting patients for treatment, SIT regimes and avoidance of adverse events. More rational and safer SIT regimes will result from new insights into the underlying immune mechanisms for allergic disease, in particular the critical role of helper T-cells in orchestrating this response. The dev...